In vitro activity of tigecycline against multidrug resistant A. baumannii isolates

Abstract number: 1733_1186

Yilmaz Bozkurt G., Memikoglu K.O., Kutlu H., Azap A., Çokça F.

Objectives:Acinetobacter baumannii is one of the important pathogens of the hospital infections. The evaluation of the in vitro activity of tigecycline in comparison to imipenem, meropenem, tazobactam-piperacillin and cefoperazone-sulbactam against Acinetobacter baumannii strains.

Methods: A total of 100 Acinetobacter baumannii clinical strains isolated during the period of September 2005–September 2006 were tested. The isolates originated from a wide variety of clinical specimens including tracheal aspirate (30), sputum (6), blood (17), central venous catheter (4), abscess-wound swabs (30), abdominal drain fluid (4), cerebrospinal fluid (1), pleural fluid (1), bile (1), urine (5). Sixty percent of these isolates was from clinics of surgery where as 40% was from internal medicine clinics. Their Minimum Inhibitory Concentration (MICs) were determined by using E-Test according to CLSI (Clinical Laboratories Standarts Institute) guidelines.

Results: Overall MIC90 to tigecycline, imipenem, meropenem, tazobactam-piperacillin and cefoperazone-sulbactam were 6 mg/L, >32 mg/L, >32 mg/L, >256 mg/L, >256 mg/L, respectively, whereas MIC50 were 2 mg/L, >32 mg/L, >32 mg/L, >256 mg/L, 32 mg/L, respectively.

Conclusion: In general, tigecycline showed better in vitro activity than imipenem, meropenem, tazobactam-piperacillin and cefoperazone-sulbactam against Acinetobacter baumanii strains. The results show that tigecycline should be considered as a possible alternative for the treatment of Acinetobacter baumannii infections.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Location: ICC, Munich, Germany
Presentation type:
Back to top